✦ In Vivo CAR-T and the Sail OptionThin moat

Johnson & Johnson (JNJ) — the future bets

J&J is paying $785 million up front for the option to buy a company that makes CAR-T therapies inside the patient's body.

J&J already knows how to sell a CAR-T therapy. Carvykti, developed with Legend, sold $1,887 million in 20251 and $657 million in the second quarter of 2026, up 49.4%2. Its growth has been limited partly by manufacturing: the filing credits 2025 growth to share gains and capacity expansion3, because each dose is made from the patient's own cells outside the body.

Sail terms and Carvykti scale ($M)785Sail initial payments465of which equity140Sail contingent657Carvykti Q2 2026 salesOption to acquire Sail for $2.58bn; J&J releases, July 2026
An option priced like one quarter of Carvykti sales.

Sail Biomedicines is a bet on removing that constraint. Its in vivo CAR-T platform is designed to generate CAR-T therapies directly within the body, enabling scalable treatments4. The first target is immune-mediated disease rather than cancer, and J&J describes the aim as resetting the immune system5.

The terms are option-shaped. J&J would make total initial payments of $785 million, including a $465 million equity investment, plus $140 million of contingent payments if development milestones are met, and holds an exclusive option to acquire Sail for $2.58 billion6. If the option is exercised J&J expects the agreements to dilute adjusted EPS by approximately $0.18 in 2026 and $1.28 in 20277.

The bet fits J&J's moat because it combines two things it already has: CAR-T experience from Carvykti and a large immunology franchise, where Tremfya grew 72.5% in the second quarter8. If in vivo CAR-T works in autoimmune disease, J&J has the physicians and the manufacturing know-how to sell it.

The equity investment is made through J&J's corporate venture capital arm, Johnson & Johnson Innovation - JJDC9, and the collaboration is with Janssen Biotech10. The structure lets J&J participate in Sail's progress before deciding whether to buy the whole company. It is a pattern J&J has used before: pay for a look, then pay for control if the science holds.

Today this is a thin moat around a potentially wide one later. In the meantime, track Carvykti's growth, the evidence that J&J can scale a cell therapy commercially; a slowdown below 30% would suggest the manufacturing lessons are not being learned fast enough to carry into a new platform.

Moat trajectory: Widening

The option was signed in July 2026; exercise depends on development milestones.

The number that tests this moat
Reported
Carvykti sales, latest quarter
$657M, +49.4% (Q2 2026)

J&J's existing cell-therapy franchise; growth below 30% would suggest the lessons of scaling are not carrying over.

Source: Johnson & Johnson Q2 2026 financial schedules ↗
References
  1. ReportedCarvykti, developed with Legend, sold $1,887 million in 2025 and $657 million in the second quarter of 2026, up 49.4%.
    Johnson & Johnson Form 10-K for fiscal 2025 (year ended 28 December 2025) - Item 1 business: segments, competition, patents, the three largest products, royalties, collaboration partners and the regulatory table. — FY2025 · publ. 11 February 2026 · source ↗
  2. ReportedCarvykti, developed with Legend, sold $1,887 million in 2025 and $657 million in the second quarter of 2026, up 49.4%.
    Johnson & Johnson second-quarter 2026 supplementary sales data, statement of earnings and non-GAAP reconciliation, Form 8-K exhibit 99.2 - Innovative Medicine and total sales by product, segment and region. — Q2 2026 · publ. 15 July 2026 · source ↗
  3. ReportedIts growth has been limited partly by manufacturing: the filing credits 2025 growth to share gains and capacity expansion, because each dose is made from the patient's own cells outside the body.
    Johnson & Johnson Form 10-K for fiscal 2025 (year ended 28 December 2025) - Item 7 MD&A: consolidated sales, volume and price, geography, the three wholesalers, rebate accruals, costs, R&D and liquidity. — FY2025 · publ. 11 February 2026 · source ↗
  4. ReportedIts in vivo CAR-T platform is designed to generate CAR-T therapies directly within the body, enabling scalable treatments.
    Johnson & Johnson announcement of agreements and an option to acquire Sail Biomedicines, Form 8-K exhibit 99.2. — July 2026 · publ. 29 July 2026 · source ↗
  5. ReportedThe first target is immune-mediated disease rather than cancer, and J&J describes the aim as resetting the immune system.
    Johnson & Johnson announcement of agreements and an option to acquire Sail Biomedicines, Form 8-K exhibit 99.2. — July 2026 · publ. 29 July 2026 · source ↗
  6. ReportedJ&J would make total initial payments of $785 million, including a $465 million equity investment, plus $140 million of contingent payments if development milestones are met, and holds an exclusive option to acquire Sail for $2.58 billion.
    Johnson & Johnson announcement of agreements and an option to acquire Sail Biomedicines, Form 8-K exhibit 99.2. — July 2026 · publ. 29 July 2026 · source ↗
  7. ReportedIf the option is exercised J&J expects the agreements to dilute adjusted EPS by approximately $0.18 in 2026 and $1.28 in 2027.
    Johnson & Johnson announcement of agreements and an option to acquire Sail Biomedicines, Form 8-K exhibit 99.2. — July 2026 · publ. 29 July 2026 · source ↗
  8. ReportedThe bet fits J&J's moat because it combines two things it already has: CAR-T experience from Carvykti and a large immunology franchise, where Tremfya grew 72.5% in the second quarter.
    Johnson & Johnson second-quarter 2026 supplementary sales data, statement of earnings and non-GAAP reconciliation, Form 8-K exhibit 99.2 - Innovative Medicine and total sales by product, segment and region. — Q2 2026 · publ. 15 July 2026 · source ↗
  9. ReportedThe equity investment is made through J&J's corporate venture capital arm, Johnson & Johnson Innovation - JJDC, and the collaboration is with Janssen Biotech.
    Johnson & Johnson announcement of agreements and an option to acquire Sail Biomedicines, Form 8-K exhibit 99.2. — July 2026 · publ. 29 July 2026 · source ↗
  10. ReportedThe equity investment is made through J&J's corporate venture capital arm, Johnson & Johnson Innovation - JJDC, and the collaboration is with Janssen Biotech.
    Johnson & Johnson announcement of agreements and an option to acquire Sail Biomedicines, Form 8-K exhibit 99.2. — July 2026 · publ. 29 July 2026 · source ↗
Sources
Generated September 24, 2026